IFNG and neuroendocrine neoplasm: Like human neuroendocrine tumor lines (Figure 3D), these early-passage mSCLC lines showed variable MHC-I induction in response to IFN-γ stimulation (Figure 4A), while pretreating cells with PRC2 inhibitors markedly potentiated IFN-γ-induced MHC-I upregulation (Figures 4D, S5D, and S5E).